docetaxel
therapeutic efficacy of CriPec
selected patients
lead product CriPec
tumour site
Tumour uptake
limited tumour
tumour heterogeneity
enhanced tumour-targeting
bladder cancer
Target Cancer Cristal Therapeutics
therapeutic responses
Nanoparticulate Precision Medicine Approach
promising clinical phase
superior therapeutic performance
clinical trials
personalized medicine
licensing deals
maximum efficacy
drug of choice
appropriate treatment
boost product development
Cristal Therapeuticsâ€™ business
current treatment options
result
parameters
adverse effects
diseases
nanomedicine platform
Imaging NM
inappropriate drugs
future patient selection
market
leading causes of death
reduced neutropenia
lab
personalisation
activity
Zr
growth
gap
alopecia
biodistribution
oncologists
state-of-the-art nanoparticles
PET tracer
generation of nanomedicines
safety profile
Success
FTE
revenues